150 related articles for article (PubMed ID: 12443730)
1. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression.
Sakai H; Noda A; Shirai N; Iidaka T; Yanai T; Masegi T; Shirai N; Iidaka T; Yanai T; Masegi T
J Comp Pathol; 2002 Nov; 127(4):233-8. PubMed ID: 12443730
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours.
Berlato D; Murphy S; Monti P; Stewart J; Newton JR; Flindall A; Maglennon GA
Vet Comp Oncol; 2015 Jun; 13(2):143-50. PubMed ID: 23489679
[TBL] [Abstract][Full Text] [Related]
3. Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors.
Joselevitch JA; Barra CN; Vargas THM; Pulz LH; Nishiya AT; Kleeb SR; Xavier JG; Catão-Dias JL; Strefezzi RF
Vet Pathol; 2018 Nov; 55(6):849-852. PubMed ID: 30025495
[TBL] [Abstract][Full Text] [Related]
4. Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry.
Zacchetti A; van Garderen E; Teske E; Nederbragt H; Dierendonck JH; Rutteman GR
APMIS; 2003 Mar; 111(3):430-8. PubMed ID: 12752223
[TBL] [Abstract][Full Text] [Related]
5. In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors.
Seung BJ; Cho SH; Kim SH; Bae MK; Lim HY; Sur JH
Vet Comp Oncol; 2021 Mar; 19(1):132-139. PubMed ID: 32926564
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclin kinase inhibitor p27(Kip1) in skin tumours of dogs.
Sakai H; Yamane T; Yanai T; Shirai N; Masegi T
J Comp Pathol; 2001; 125(2-3):153-8. PubMed ID: 11578131
[TBL] [Abstract][Full Text] [Related]
7. Assessment of proliferative potentials of canine osteosarcomas and chondrosarcomas by MIB-1 immunohistochemistry and bromodeoxyuridine incorporation.
Ohta G; Sakai H; Kachi S; Hirata A; Yonemaru K; Kitajima A; Yanai T; Masegi T
J Comp Pathol; 2004 Jul; 131(1):18-27. PubMed ID: 15144796
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fibroblast Activating Protein and Correlation with Histological Grade, Mitotic Index and Ki67 Expression in Canine Mast Cell Tumours.
Giuliano A; Dos Santos Horta R; Constantino-Casas F; Hoather T; Dobson J
J Comp Pathol; 2017 Jan; 156(1):14-20. PubMed ID: 27889201
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous mast cell tumour within a lipoma in a boxer.
Jakab C; Szász AM; Kulka J; Schaff Z; Rusvai M; Németh T; Gálfi P
Acta Vet Hung; 2009 Jun; 57(2):263-74. PubMed ID: 19584039
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical evaluation of proliferative activity in human brain tumours.
Girino M; Riccardi A; Danova M; Gaetani P; Butti G; Giordano M; Cuomo A
Anal Cell Pathol; 1990 Sep; 2(5):269-75. PubMed ID: 2275874
[TBL] [Abstract][Full Text] [Related]
11. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM
Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical identification method of tumour cells in the S phase of mitotic cycle and its usefulness in diagnostics of mammary gland adenocarcinomas in bitches.
Nowak M; Madej JA; Dziegiel P; Kanzawa H
Pol J Vet Sci; 2006; 9(1):57-62. PubMed ID: 16573276
[TBL] [Abstract][Full Text] [Related]
13. Cytological grading of canine cutaneous mast cell tumours.
Scarpa F; Sabattini S; Bettini G
Vet Comp Oncol; 2016 Sep; 14(3):245-51. PubMed ID: 24717019
[TBL] [Abstract][Full Text] [Related]
14. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of markers of cell proliferation in canine mast cell tumours according to current classifications.
Kandefer-Gola M; Madej JA; Dzimira S; Nowak M; Janus I; Ciaputa R
Pol J Vet Sci; 2015; 18(2):241-7. PubMed ID: 26172171
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.
Rodriguez S; Fadlalla K; Graham T; Tameru B; Fermin CD; Samuel T
J Comp Pathol; 2012; 147(2-3):171-6. PubMed ID: 22289273
[TBL] [Abstract][Full Text] [Related]
17. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
Fröberg GK; Lindberg R; Ritter M; Nordlind K
J Comp Pathol; 2009; 141(2-3):89-97. PubMed ID: 19446835
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
[TBL] [Abstract][Full Text] [Related]
19. Concentration of extracellular vesicles isolated from blood relative to the clinical pathological status of dogs with mast cell tumours.
Šimundić M; Švara T; Štukelj R; Krek JL; Gombač M; Kralj-Iglič V; Tozon N
Vet Comp Oncol; 2019 Dec; 17(4):456-464. PubMed ID: 31066969
[TBL] [Abstract][Full Text] [Related]
20. TSLC1 tumour-suppressor gene expression in canine mast cell tumours.
Taylor F; Murphy S; Hoather T; Dobson J; Scase T
Vet Comp Oncol; 2010 Dec; 8(4):263-72. PubMed ID: 21062408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
